These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1388 related articles for article (PubMed ID: 18503402)

  • 1. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
    Smith D; Bosacki C; Merrouche Y
    Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on panitumumab in metastatic colorectal cancer.
    Keating GM
    BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.
    Peeters M; Cohn A; Köhne CH; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):14-23. PubMed ID: 21925954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
    Saif MW; Kaley K; Chu E; Copur MS
    Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.